Managing herpes zoster in immunocompromised patients

Herpes

Volumn 14, Issue 2, 2007, Pages 32-36

  Ahmed, Ammar M ^a   Brantley, Julie S ^b   Madkan, Vandana ^c   Mendoza, Natalia ^c   Tyring, Stephen K ^c,d,e  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c CENTER FOR CLINICAL STUDIES   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e NONE   (United States)

Author keywords

Antivirals; Herpes zoster; HIV; Immunocompromised; Management; Transplant; Treatment; Varicella zoster virus

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ANALGESIC AGENT; ANTIVIRUS AGENT; BROMOVINYLURACIL; CIDOFOVIR; COCODAMOL; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLIZING ENZYME; FAMCICLOVIR; FLUCYTOSINE; FLUOROURACIL; FOSCARNET; INTERFERON; NARCOTIC ANALGESIC AGENT; PARACETAMOL; SORIVUDINE; UNCLASSIFIED DRUG; URACIL DERIVATIVE; VALACICLOVIR; VIDARABINE;

AREA UNDER THE CURVE; BONE MARROW TOXICITY; CANCER PATIENT; CLINICAL TRIAL; DISEASE SEVERITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG INDICATION; DRUG METABOLISM; DRUG WITHDRAWAL; FOLLOW UP; GENITAL HERPES; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; KIDNEY FAILURE; NERVE BLOCK; OUTPATIENT; PAIN; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; RASH; RECURRENCE RISK; RELAPSE; REVIEW; SUPERINFECTION; TOPICAL TREATMENT; TRANSCUTANEOUS NERVE STIMULATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ALGORITHMS; ANALGESICS; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; DISEASE MANAGEMENT; DRUG THERAPY, COMBINATION; FEMALE; HERPES ZOSTER; HUMANS; IMMUNOCOMPROMISED HOST; PAIN;

HERPES ZOSTER; HUMAN HERPESVIRUS 3;

EID: 35048866419     PISSN: 09697667     EISSN: 14701537     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Buchbinder SP, Katz MH, Hessol NA, Liu JY, O'Malley PM, Underwood R et al. Herpes zoster and human immunodeficiency virus infection. J Infect Dis 1992;166:1153-1156.
2. Berman JN, Wang M, Berry W, Neuberg DS, Guinan EC. Herpes zoster infection in the post-hematopoietic stem cell transplant pediatric population may be preceded by transaminitis: an institutional experience. Bone Marrow Transplant 2006;37:73-80.
3. Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant 2004;4:108-115.
4. Gershon AA. Prevention and treatment of VZV infections in patients with HIV. Herpes 2001;8:32-36.
5. Glesby MJ, Moore RD, Chaisson RE. Clinical spectrum of herpes zoster in adults infected with human immunodeficiency virus. Clin Infect Dis 1995;21:370-375.
6. Gnann J, Whitley RJ. Natural history and treatment of varicella-zoster virus in high-risk populations. J Hosp Infect 1991;18:317-329.
7. Merigan TC, Rand KH, Pollard RB, Abdallah PS, Jordan GW, Fried RP. Human leukocyte interferon for the treatment of herpes zoster in patients with cancer. N Engl J Med 1978;298:981-987.
8. Whitley RJ, Soong SJ, Dolin R, Betts R, Linnemann C Jr, Alford CA Jr. Early vidarabine therapy to control the complications of herpes zoster in immunosuppressed patients. N Engl J Med 1982;307:971-975.
9. Balfour HH Jr, Bean B, Laskin OL, Ambinder RF, Meyers JD, Wade JC et al. Acyclovir halts progression of herpes zoster in immunocompromised patients. N Engl J Med 1983;308:1448-1453.
10. Shepp DH, Dandliker PS, Meyers JD. Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine. N Engl J Med 1986;314:208-212.
11. Nagafuchi S, Moriyama K, Takamatsu Y, Hayashi S, Niho Y, Takenaka A et al. Treatment of disseminated herpes zoster in six severely immunocompromised patients: acyclovir and vidarabine. Jpn J Med 1989;28:100-104.
12. Ljungman P, Lonnqvist B, Ringden O, Skinhoj P, Gahrton G. A randomized trial of oral versus intravenous acyclovir for treatment of herpes zoster in bone marrow transplant recipients. Nordic Bone Marrow Transplant Group. Bone Marrow Transplant 1989;4:613-615.
13. Beutner KR, Friedman DJ, Forszpaniak C, Andersen PL, Wood MJ. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39:1546- 1553.
14. Brentjens MH, Torres G, He J, Lee PC, Tyring SK. A double-blind, randomized study of the use of 2 grams vs. 1 gram valacyclovir TID for 7 days in the treatment of acute herpes zoster in immunocompromised individuals (poster 455). 61st Annual Meeting of the American Academy of Dermatology, San Francisco, USA, 2003.
15. Tyring SK, Belanger R, Bezwoda W, Ljungman P, Boon R, Saltzman RL. A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients. Cancer Invest 2001;19:13-22.
16. Andrei G, Snoeck R. Reymen D, Liesnard C, Goubau P, Desmyter J et al. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus. Eur J Clin Microbiol Infect Dis 1995;14:318-329.
17. Machida H. Comparison of susceptibilities of varicella-zoster virus and herpes simplex virus to nucleoside analogs. Antimicrob Agents Chemother 1986;29:524-526.
18. Shigeta S, Yokota T, Iwabuchi T, Baba M, Konno K, Ogata M et al. Comparative efficacy of antiherpes drugs against various strains of varicella-zoster virus. J Infect Dis 1983;147:576-584.
19. Tricot G, De Clercq E, Boogaerts MA, Verwilghen RL. Oral bromovinyldeoxyuridine therapy for herpes simplex and varicella-zoster virus infections in severely immunosuppressed patients: a preliminary clinical trial. J Med Virol 1986;18:11-20.
20. Wutzler P, De Clercq E, Wutke K, Farber I. Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. J Med Virol 1995;46:252-257.
21. Wassilew S, Collaborative Brivudin PHN Study Group. Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients. A randomized, double-blind, multinational study. J Eur Acad Dermatol Venereol 2005;19:47-55.
22. Wassilew SW, Wutzler P, Brivddin Herpes Zoster Study Group. Oral brivudin in comparison with acyclovir for improved therapy of herpes zoster in immunocompetent patients: results of a randomized, double-blind, multicentered study. Antiviral Res 2003;59:49-56.
23. Bodsworth NJ, Boag F, Burdge D, Genereux M, Borleffs JC, Evans BA et al. Evaluation of sorivudine (BV-araU) versus acyclovir in the treatment of acute localized herpes zoster in human immunodeficiency virus-infected adults. The Multinational Sorivudine Study Group. J Infect Dis 1997;176:103-111.
24. Gnann JW Jr, Crumpacker CS, Lalezari JP, Smith JA, Tyring SK, Baum KF et al. Sorivudine versus acyclovir for treatment of dermatomal herpes zoster in human immunodeficiency virus-infected patients: results from a randomized, controlled clinical trial. Collaborative Antiviral Study Group/ATDS Clinical Trials Group, Herpes Zoster Study Group. Antimicrob Agents Chemother 1998;42:1139-1145.
25. Arvin AM. Antiviral therapy for varicella and herpes zoster. Semin Pediatr Infect Dis 2002;13:12-21.
26. Arvin AM. Varicella-zoster virus: pathogenesis, immunity, and clinical management in hematopoietic cell transplant recipients. Biol Blood Marrow Transplant 2000;6:219-230.
27. Breton G, Bouldouyre MA, Gervais A, Duval X, Longuet P, Leport C et al. Failure of valacyclovir for herpes zoster in a moderately immunocompromised HIV-infected patient. AIDS Patient Care STDS 2004;18:255-257.
28. Reusser P. Herpesvirus resistance to antiviral drugs: a review of the mechanisms, clinical importance and therapeutic options. J Hosp Infect 1996;33:235-248.
29. Balfour HH Jr, Benson C, Braun J, Cassens B, Erice A, Friedman-Kien A et al. Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. J Acquir Immune Defic Syndr 1994;7:254-260.
30. Breton G, Fillet AM, Katlama C, Bricaire F, Caumes E. Acyclovir-resistant herpes zoster in human immunodeficiency virus-infected patients: results of foscarnet therapy. Clin Infect Dis 1998;27:1525-1527.
31. Snoeck R, Andrei G, Clercq ED. Novel agents for the therapy of varicella-zoster infections. Expert Opin Investig Drugs 2000;91743-1751.
32. Locksley RM, Flournoy N, Sullivan KM, Meyers JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985;152:1172-1181.
33. Koc Y, Miller KB, Schenkein DP, Griffith J, Akhtar M, DesJardin J et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 2000;6:44-49.
34. Balfour HH Jr. Varicella zoster virus infections in immunocompromised hosts. A review of the natural history and management. Am J Med 1988;85:68-73.
35. Harrison RA, Soong S, Weiss HL, Gnann JW Jr, Whitley RJ. A mixed model for factors predictive of pain in ADDS patients with herpes zoster. J Pain Symptom Manage 1999;17:410-417.